CORONA Remedies Limited reported a robust financial performance for the second quarter and first half of FY26, supported by healthy revenue growth, margin stability, and strong return ratios.
Q2FY26 Financial Performance
For the quarter ended September 30, 2025, CORONA Remedies posted consolidated revenue from operations of ₹361.13 crore, marking a year-on-year growth of 15.1%.Profit after tax for the quarter stood at ₹52.32 crore, reflecting a 21.8% increase compared with the corresponding period last year. The company maintained a profit after tax margin of 14.5% during the quarter.
EBITDA for Q2FY26 came in at ₹78.47 crore, with an EBITDA margin of 21.7%, indicating continued operating efficiency.
H1FY26 Performance Highlights
For the first half of FY26, consolidated revenue from operations rose to ₹707.67 crore, registering a year-on-year growth of 17.0%.Profit after tax for the half year stood at ₹98.52 crore, representing a strong 35.1% growth over the same period last year. The PAT margin for H1FY26 was reported at 13.9%.
EBITDA for the half year reached ₹148.25 crore, translating into an EBITDA margin of 20.9%.
Return Ratios and Cash Flow Metrics
The company reported healthy return metrics for H1FY26, with annualised return on equity at 31.1% and return on capital employed at 49.7%.Operating cash flow to EBITDA stood at 76.5%, while net working capital days were maintained at 23 days, reflecting disciplined working capital management.
Management Commentary
Commenting on the performance, the Managing Director and Chief Executive Officer stated that the company delivered strong growth across both revenue and profitability during Q2 and H1FY26 while maintaining healthy return ratios.The management highlighted consistency in strategy execution, continued focus on core therapeutic segments, expansion of the brand portfolio, strengthening of the field force, and sustained emphasis on specialist prescriptions as key drivers supporting performance and long-term growth.
Earnings Call
The company will conduct its earnings call at 12:00 PM IST on January 5, 2026, to discuss financial and business performance for the quarter and half year.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.